ir.halozyme.comHalozyme Therapeutics, Inc. - Investor
ir.halozyme.com Profile
Ir.halozyme.com is a subdomain of halozyme.com, which was created on 2003-12-08,making it 20 years ago.
Discover ir.halozyme.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.halozyme.com Information
| HomePage size: 84.283 KB |
| Page Load Time: 0.249297 Seconds |
| Website IP Address: 162.159.129.11 |
ir.halozyme.com Similar Website
| Aratana Therapeutics Investor Overview |
| Synopsys, Inc. | Investor Relations & Investor Resources |
| Masonite International Corp. - Investor Relations - Investor Relations |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) |
| Investor Relations | TG Therapeutics, Inc. |
| Revance Therapeutics, Inc. - Investor Relations |
| Investor Overview | Mateon Therapeutics |
| Coya Therapeutics - Investor Relations |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) |
| United Therapeutics Investor Relations |
| Mirati Therapeutics Inc. - Investor & Media Relations |
| Edgewise Therapeutics, Inc. - Investor |
| Cyteir Therapeutics - Investor |
ir.halozyme.com PopUrls
| Halozyme Therapeutics, Inc. - Investor Relations https://ir.halozyme.com/overview/default.aspx |
| News https://ir.halozyme.com/news/default.aspx |
| Stock Info https://ir.halozyme.com/stock-info/default.aspx |
| Privacy Policy https://ir.halozyme.com/privacy-policy/default.aspx |
| Financials - Annual Reports https://ir.halozyme.com/financials/annual-reports/default.aspx |
| Financials - SEC Filings https://ir.halozyme.com/financials/sec-filings/default.aspx |
| Events & Presentations https://ir.halozyme.com/events-and-presentations/default.aspx |
| Financials - Quarterly Results https://ir.halozyme.com/financials/quarterly-results/default.aspx |
| Resources - Investor FAQs https://ir.halozyme.com/resources/investor-faqs/default.aspx |
| Events & Presentations - Halozyme Therapeutics, Inc. https://ir.halozyme.com/events-and-presentations/presentations/default.aspx |
| Halozyme Therapeutics, Inc. - Fourth Quarter and Full Year 2021 ... https://ir.halozyme.com/events-and-presentations/presentations/presentation-details/2022/Fourth-Quarter-2021-Financial-Results-Presentation/default.as |
| Halozyme Therapeutics, Inc. - Third Quarter 2022 Financial Results ... https://ir.halozyme.com/events-and-presentations/presentations/presentation-details/2022/Third-Quarter-2022-Financial-Results-Presentation/default.asp |
| Halozyme Therapeutics, Inc. - Stock Info - Analyst Coverage https://ir.halozyme.com/stock-info/analyst-coverage/default.aspx |
| Halozyme Therapeutics, Inc. - Halozyme To Host Fourth Quarter and Full ... https://ir.halozyme.com/events-and-presentations/events/event-details/2022/Halozyme-To-Host-Fourth-Quarter-And-Full-Year-2021-Financial-Results-Webcas |
ir.halozyme.com Httpheader
| Date: Thu, 16 May 2024 22:54:50 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 884ef3ade9eacf15-SJC |
| CF-Cache-Status: REVALIDATED |
| Cache-Control: public, max-age=10, stale-if-error=86400, stale-while-revalidate=86400 |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Vary: Accept-Encoding |
| X-Content-Type-Options: nosniff |
| X-Frame-Options: SAMEORIGIN |
| X-XSS-Protection: 1; mode=block |
| Server: |
ir.halozyme.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-type"/ |
| content="RevealTrans(Duration=0,Transition=0)" http-equiv="Page-Enter"/ |
| content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
| content="default-src 'self' https: http: 'unsafe-inline' 'unsafe-eval' *.q4inc.com; script-src 'self' *.cloudfront.net *.pusherapp.com *.newrelic.com *.nr-data.net *.bugherd.com *.q4cdn.com *.q4web.com *.amazonaws.com *.highcharts.com *.googletagmanager.com *.googleadservices.com *.google-analytics.com *.google.com *.gstatic.com *.q4app.com *.pendo.io 'unsafe-inline' 'unsafe-eval' *.q4inc.com" http-equiv="Content-Security-Policy"/ |
| content="WD7_9gcB3XmeFlJZ9vsijZrcWcWYUDMtZBNXkKwANaQ" |
ir.halozyme.com Html To Plain Text
Relations Overview News Events & Presentations Events Presentations Stock Info Stock Information Stock Chart Historical Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Team Board of Directors Commitment to ESG Resources Investor FAQs Email Alerts Contact Us Investor Relations Overview News Events & Presentations Events Presentations Stock Info Stock Information Stock Chart Historical Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents Leadership Team Board of Directors Commitment to ESG Resources Investor FAQs Email Alerts Contact Us Corporate Overview At Halozyme, we are focused on new and proven therapeutic approaches. We are driven to bring innovative and disruptive solutions and support to partners with a goal of significantly improving patient experiences, and potentially outcomes, for emerging and established therapies. Latest News View all news Latest Presentation Latest Events View All Events Latest Quarterly Reports View All Financial Reports Contact Us Tram Bui Vice President, Investor Relations & Corporate Communications 609-359-3016 [email protected] [email protected] [email protected] Al Kildani Vice President, Investor Relations & Corporate Communications 858-704-8122 akildani@halozyme.com media@halozyme.com ir@halozyme.comQuick Links SEC Filings Investor FAQs Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Halozyme Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Halozyme Therapeutics to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Events & Presentations Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Unsubscribe Email Alert Sign Up Confirmation Privacy Policy Cookies Policy © Q4 Inc. - All rights reserved Powered By Q4 Inc. 5.122.0.3 (opens in...
ir.halozyme.com Whois
Domain Name: HALOZYME.COM Registry Domain ID: 107916827_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2022-09-22T01:20:39Z Creation Date: 2003-12-08T20:04:28Z Registry Expiry Date: 2025-12-08T20:04:28Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS29.DOMAINCONTROL.COM Name Server: NS30.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-18T08:12:30Z <<<